RT Journal Article SR Electronic T1 2022-RA-1149-ESGO Oxaliplatin-based treatments are currently a valid therapeutic option in heavily pretreated ovarian cancer patientswith hypersensitivity reactions (HRs) to carboplatin in the antiangiogenics and PARPi era JF International Journal of Gynecologic Cancer JO Int J Gynecol Cancer FD BMJ Publishing Group Ltd SP A306 OP A306 DO 10.1136/ijgc-2022-ESGO.652 VO 32 IS Suppl 2 A1 Inoa, Jennifer Olalla A1 Escudero, Laura Sanchez A1 Manzano, Aranzazu A1 Marquina, Gloria A1 Coronado, Pluvio A1 Garcia-santos, Francisco Javier A1 Bellon, Monica A1 Morillas, Leticia Sanchez A1 Rivas, Montserrat Fernandez A1 Fernandez, Ramiro Mendez A1 Segura, Pedro Perez A1 Casado, Antonio YR 2022 UL http://ijgc.bmj.com/content/32/Suppl_2/A306.1.abstract AB Introduction/Background Oxaliplatin, in the era prior to antiangiogenics and PARPi therapies, demonstrated activity in patients (pts) with ovarian cancer (OC) in phase I, II and III studies. Oxaliplatin may play a role in pts with hypersensitivity reactions (HRs) to carboplatin.Methodology Single-institution retrospective experience (2004–2022) in terms of efficacy and safety with oxaliplatin in recurrent OC, especially in pts with HRs to carboplatin.SPSS version 22.0 was used for statistical analysesResults 68 pts were treated with oxaliplatin (monotherapy, 25%, in combination 75%, mostly with gemcitabine (56.4%) or paclitaxel (15,1%). Pts and disease characteristics are shown in Table 1. Median progression free survival (mPFS) and overall survival (mOS) were 3 and 13 months (m), respectively. There was no difference between platinum-resistant and platinum-sensitive in terms of PFS, but there was a benefit in mOS in platinum-sensitive disease (13 vs 6 m). Pts who attained controlled disease with oxaliplatin showed a mPFS of 6 months and mOS of 15 months. 45.9% of patients had experienced prior HRs to carboplatin; 67% of them did not require desensitization to oxaliplatin. However, 17.8% of the patients suffered HRs to oxaliplatin. PARPi before oxaliplatin was used in 5 pts. Of them, two stable diseases were achieved with no objective responses. Pts with clinical benefit to oxaliplatin and who had received prior bevacizumab had a 64% lower risk of progression (HR 0.36 IC 95% 0.169–0.800,p 0.012), and patients with no benefit from oxaliplatin had a better outcome with the previous use of bevacizumab (HR 0.20, IC 95% 0.064 – 0.679,p=0.009). Grade 3/4 toxicity was observed in 36.8%, mainly hematological and gastrointestinal toxicity.View this table:Abstract 2022-RA-1149-ESGO Table 1 Conclusion Oxaliplatin improves PFS and OS in pts with OC recurrent setting, in particular in those pts not candidates to receive carboplatin-based regimens mainly due to HRs. Oxaliplatin is currently a valid treatment.